There is little question as to the ef®cacy of sildena®l citrate (Viagra TM ) for the treatment of erectile dysfunction. Two years of post-marketing experience provide data which indicates that the ef®cacy and safety of sildena®l citrate is consistent with the data obtained in clinical trials. This paper provides an update of the clinical ef®cacy and safety of sildena®l collected since its
Introduction
After evaluation in 21 prospective, randomized, placebo-controlled clinical studies, sildena®l citrate (Viagra TM ) became the ®rst FDA approved oral treatment for erectile dysfunction (ED) on 27 March, 1998. The sildena®l clinical trials were designed to re¯ect and predict real-world experience and the database included patients representative of the ED population. Indeed, the pro®le of patients currently receiving sildena®l prescriptions is similar to that of the men who were enrolled in the clinical trials. 1 Long-term open-label extension studies provide data from patients with over 8000 personay of exposure to sildena®l citrate. 1, 2 The post-marketing exposure of patients to sildena®l is indeed substantial. As of May 2000, more than 6 million patients have used it and approximately 260,000 doctors have written over 20 million prescriptions for sildena®l. In the month of March 2000 alone, 381,000 new and 545,000 re®ll prescriptions were written. All together, over 100 million pills have been dispensed. 3 The objective of this manuscript is to summarize the clinical experience with sildena®l, with emphasis on ef®cacy and safety data collected from ongoing clinical trials as well as from post-marketing publications.
Clinical ef®cacy update
Clinical trial data demonstrated that up to 82% of men taking sildena®l reported improvement in erections compared with 24% of men taking placebo, a ®nding that is highly statistically signi®cant. 4 ± 6 Furthermore, the sildena®l treatment group reported a 79% improvement over baseline in the ability to achieve an erection compared to 11% for the placebo group. Sildena®l also produced a 106% improvement over baseline in the ability of those treated to maintain an erection vs 19% in the placebo group. Ef®cacy was present regardless of patient age, the etiology of ED (organic, psychogenic, mixed) and baseline severity of the condition. Men with concomitant ischemic heart disease and those taking single and multiple anti-hypertensive medications were included in the placebocontrolled studies and these patients also responded to sildena®l. 1, 7 Certain groups of men fared better than others, however. In a retrospective analysis of the clinical trials database, psychogenic patients responded the best (85%) followed by spinal cord injured males (82%), patients with hypertension (68%), patients who recently underwent transurethral resection of the prostate (61%), diabetics (57%) and, ®nally, radical prostatectomy patients demonstrated the lowest response rate (43%). 1 Data from a 24 month interim evaluation of 738 men with ED enrolled in an open-label extension study is currently available. Assessment of therapeutic response was established by asking the men to answer two questions: (1) are you satis®ed with the effect that the treatment you have been receiving is having on your erections? (2) Has the treatment improved your ability to engage in sexual activity? Responses of`yes' to questions (1) and (2) were 96.5% and 99.96%, respectively. 8 Post-marketing publications have also demonstrated ef®cacy of sildena®l in speci®c patient populations. Improved erections were reported by 70% of patients with ischemic heart disease who received sildena®l compared to 20% of similarly diagnosed men who received placebo. 7, 9 Over 50% of these men were treated concurrently with antihypertensive agents, beta blockers (17%) or diuretics (9%). 1,7,9 Ef®cacy of sildena®l in male heart transplant patients was also observed. Although sildena®l is effective in this group of patients, the number of patients treated was small and there is no long-term follow-up data available. 10, 11 Another group of patients of great interest to urologists are those who are rendered impotent after prostate cancer treatment. Sixty-six percent of patients with ED due to prostate cancer treatment with three-dimensional external beam radiotherapy experienced improvement of erection with sildena®l 12 and 80.6% men responded favorably to sildena®l following prostate brachytherapy. 13 The presence or absence of intact neurovascular bundles after radical prostatectomy in¯uenced the erectile response to sildena®l. When both neurovascular bundles were spared, 71.7% of men responded to sildena®l compared to 50% and 15.4% of men who underwent unilateral nerve-sparing and nonnerve-sparing prostatectomy, respectively. 14 Following bilateral nerve-sparing surgery, response to sildena®l appears to be dependent upon the time interval between the radical prostatectomy and the initiation of sildena®l treatment. Treatment satisfaction rate was found to peak at 60% between 18 months and 2 years following radical prostatectomy. 15 Finally, Jarow et al attempted to establish predictors of satisfactory treatment outcome with sildena®l. In their study, ef®cacy varied and was dependent upon baseline sexual function and etiology, but there was no group of patients in whom sildena®l completely lacked ef®cacy. Moreover, no patient characteristic was identi®ed that could predict absolute failure to sildena®l therapy. 16 
Adverse events and safety
Adverse events or side effects related to vasodilation are the most commonly observed post-sildena®l ingestion. Consistent with its mechanism of action, headaches (16%),¯ushing (10%), nasal congestion (4%) and gastro-esophageal re¯ux (7%) occur approximately 1 h after intake and are the most common patients' complaints. 1,4 ± 6 Visual disturbances (blue-green hues, hypersensitivity to light) occur in 3% of men and dizziness in 2% of men post-sildena®l. 4 All adverse events are transient and reversible. Overall, discontinuation of sildena®l because of adverse events of all types in placebocontrolled studies was comparable in the sildena®l (2.5%) and placebo (2.3%) groups. 17 Long-term cardiovascular safety and, in particular, the potential for sildena®l to cause death andaor serious adverse events in men with ischemic heart disease are of primary concern. Although the concomitant use of sildena®l with other vasoactive drugs, particularly in men taking several antihypertensive medications, continues to be an issue for some physicians and patients, several publications indicate that concomitant use of these medications is well tolerated.
Myocardial infarction and death
Placebo-controlled long-term clinical trial data provides the most accurate determination of whether there is a causal relationship between pharmacological treatment with sildena®l and serious adverse events such as myocardial infarction (MI) and death. Data reporting the incidence rate of MI and mortality (all causes) from exposure to sildena®l in 53 clinical trials (6884 patients years for sildena®l (964 double-blind; 5920 open label) and 543 patient years for placebo) is available through 31 March, 1999. 2 The rates of MI (Table 1) and death (Table 2 ) among men with ED treated with sildena®l were similar to those observed in men randomized to placebo. 8 Post-marketing data collected to date on sildena®l reveal that the rate of death andaor of serious adverse events reported to FDA is not inconsistent with the baseline mortality rate in men of this age and health status. 18 
Anti-hypertensive medication interaction
The phase IIaIII studies of sildena®l included a signi®cant proportion of patients with hypertension, many of whom were being treated with antihypertensive medications. Of 2722 patients treated with sildena®l in clinical trials, 885 (32.5%) received concomitant anti-hypertensive medications (as did 32.7% of placebo-treated patients). These medications included: calcium-channel blockers, ACE inhibitors, alpha blockers, beta blockers, and diuretics administered as monotherapy or in combination. Results show that patients who take anti-hypertensive medication are not at higher risk of developing symptoms associated with blood pressure lowering when they take sildena®l. 19 Because sildena®l inhibits type V phosphodiesterase which has a direct impact on the NOcGMP system, the action and hypotensive effects of NO donors such as nitrates will be potentiated; thus, sildena®l is absolutely contraindicated in men being treated with organic nitrates regardless of their dosage form and schedule of administration.
Dosage and administration
Consistent with its mode of action on the NO-cGMP system, sildena®l will not initiate an erection nor exert its effect in the absence of sexual stimulation. Although younger men may experience bene®t from sildena®l as early as 30 min post ingestion; older men may need 1 ± 1 1 2 h before an optimal effect on erection is noted. Indeed, clinical experience reveals that sexual activity prior to complete absorption may result in diminished overall effectiveness. One can postulate that, in the absence of complete inhibition of PDE 5 , partial dephosphorylation of cGMP will decrease the erectile response.
Retrospective analysis of clinical trial data reveals that two-thirds of men who responded to sildena®l had a successful intercourse attempt on the ®rst or second use the drug. However, the remaining third of ED patients required up to six more uses of sildena®l until they had their ®rst successful attempt at intercourse. This is indicative of the fact that many factors contribute to a successful intercourse attempt, including patient (and partner) anxiety. Therefore, men who do not initially achieve a successful erection should be encouraged to try sildena®l up to a maximum dose of 100 mg on six to eight different occasions before a lack of response is considered. Although most men started at the 50 mg dose, 75% ultimately selected the 100 mg dose.
Drugs that are potent inhibitors of the cytochrome P450-3A4 isoenzyme (eg erythromycin, ketoconazole, ritonavir) will result in increased plasma and tissue levels of sildena®l when taken concomitantly. Finally, sildena®l absorption and serum peak levels will be diminished if the drug is taken with fatty food.
It is common for men who suffer from organic ED to also have various degrees of`performance anxiety' when re-engaging in sexual activity. Therefore, in order to maximize early success with sildena®l, men should be encouraged to take the drug on an empty stomach, and avoid using it when fatigued, ie, late at night, and after alcohol ingestion.
Conclusion
Sildena®l citrate is the ®rst and only effective oral treatment for ED approved by the FDA. Effectiveness across a broad range of etiologic pro®les has been demonstrated. Baseline sexual function and etiology of ED impacts the response to sildena®l. No patient characteristic that would predict failure is currently available and, in the absence of contraindications, all patients with ED should be considered for sildena®l therapy. Adverse events are mild, tolerable and very few patients will discontinue use of sildena®l because of side effects. The only absolute contraindication for sildena®l is the concomitant use of organic nitrates. However, since sex may constitute vigorous aerobic activity, for men with ED who may have been abstinent for a signi®cant period of time, clinicians should always consider the impact of sex on their cardiovascular system before prescribing any treatment for ED, including sildena®l. In randomized, placebo-controlled clinical trials, the incidence rate of serious adverse events, including myocardial infarctions among men with ED treated with sildena®l were low and similar to those observed in men randomized to placebo. Epidemiological data collected in the 2 y postmarketing period following sildena®l's approval reveals that the death rate and rate of other serious adverse events is not excessive given the baseline mortality rate in a population of men with similar age and health status. Maximum bene®t is obtained if sildena®l is taken correctly. 
